Israel 's MyHeritage has launched a single health and ancestry test , becoming the latest ancestry DNA firm to expand into health monitoring after competitors like 23andMe . The test produces genetic data on diseases including type 2 diabetes , hereditary breast cancer , heart disease , late - onset Alzheimer ’s disease , late - onset Parkinson ’s disease , Tay - Sachs disease and cystic fibrosis . The $ 199 kits are processed in a laboratory certified under US Clinical Laboratory Improvement Amendments regulations , but the test has reportedly not been approved by the Food and Drug Administration . In the US , MyHeritage is working with PWNHealth to offer counselling and contact with medical professionals .
Israel's MyHeritage has launched a single health and ancestry test, becoming the latest ancestry DNA firm to expand into health monitoring after competitors including 23andMe. The test produces genetic data on conditions including type 2 diabetes, hereditary breast cancer, heart disease, late-onset Alzheimer’s disease, late-onset Parkinson’s disease, Tay-Sachs disease and cystic fibrosis. The $199 kits are processed in a laboratory certified under US Clinical Laboratory Improvement Amendments regulations, but the test has reportedly not been cleared by the Food and Drug Administration. In the US, MyHeritage is working with PWNHealth to offer counselling and contact with medical professionals.